Proton Therapy for Mediastinal Lymphoma in Denmark

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This national trial examines the feasibility of delivering proton therapy for mediastinal lymphoma across Danish centers and compares the calculated toxicity risk reduction from proton plans to the actually delivered plans. It prospectively collects acute and late side effects and explores a model-based approach to selecting patients for proton therapy. Eligible patients are adults with Hodgkin or non-Hodgkin lymphoma whose disease is confined to the mediastinum ± neck/axilla and who are planned for curative treatment. The study documents treatment plans, delivery, and toxicity outcomes to understand real-world differences between predicted and delivered toxicity risks. Participation requires informed consent and adherence to follow-up visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients 18 years or older
* Histologically proven Hodgkin or non-Hodgkin lymphoma
* Disease constrained within the mediastinum +/- neck and/or axilla involvement.
* Candidates for curative intended treatment
* Signed written informed consent.

Exclusion Criteria:

* Prior radiotherapy to the thorax
* Other current malignancy
* Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic.

Where it's running

• Dept. of oncology
  Copenhagen, Select A State, Denmark Recruiting

Study contacts

• Study coordinator: Mogens Bernsdorf, Md. Phd
• Email: mogens.bernsdorf@regionh.dk
• Phone: +4535459681

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Pomalidomide, anti–PD‑1 antibody, and selinexor for relapsed/refractory primary CNS diffuse large B‑cell lymphoma

  This trial tests whether combining pomalidomide, a PD‑1 blocking antibody, and selinexor can help adults with relapsed or refractory primary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07523737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.